Kenneth I. Moch - Aug 3, 2021 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Director
Signature
/s/ Suzanne M. Hanlon, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
4
Date filed
8/5/2021, 05:21 PM
Next filing
Jan 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +5K $0.00 5K Aug 3, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYNE Stock Option (right to buy) Award $0 +7.5K $0.00 7.5K Aug 3, 2021 Common Stock 7.5K $4.44 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders.
F2 The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders.